|A Preliminary Bibliography on Injection Drug Use and Users (IDU) in Canada.
A work in progress: comments and additional references are welcome.
Please forward to the contact below.
Produced with financial support from the
National Network for Aboriginal Mental Health Research.
Maija Prakash (PhD Candidate, Department of Anthropology, University of Alberta)
Chris Fletcher (Assistant Professor, Department of Anthropology, University of Aberta)
Dr. Christopher Fletcher
Department of Anthrpology
Tory Building 13-5
University of Alberta
Canada T6G 2H4
National Task Force on HIV, AIDS and Injection Drug Use HIV, AIDS and injection drug use: a national action plan. 1997. Ottawa, Canadian Public Health Association. This project was funded by the AIDS Prevention & Community Action Program under the National AIDS Strategy, in collaboration with Canada's Drug Strategy, Health Canada
Parliamentary Committee Report on Non Medical Use of Drugs.
Adlaf EM, Zdanowicz YM, Smart RG (1996) Alcohol and other drug use among street-involved youth in Toronto. Addiction Research 4:11-24
Altman J . Health Strategy for IV Drug Users in the Downtown Eastside. 1998. Vancouver, Vancouver/Richmond Health Board.
Anis AHeal (2002) Leaving hospital against medical advice among HIV-positive patients. CMAJ 167:633-637
Archibald C . The Point Project: A Study of Risk Factors for HIV Infection Among Vancouver's Injection Drug Using Community. 1996. Vancouver, B.C.
Bardsley J, Turvey J, Blatwick J (1990) Vancouver's Needle Exchange Program. Canadian Journal of Public Health 81:39-45
BC Centre for Excellence in HIV/AIDS. Project Update: VIDUS (Vancouver Injection Drug User Study). Forecast 6[3&4], 6. 1998.
Belanger D, et al. Factors explaining the intention to use condoms among injection drug usersparticipating in a needle-exchange program. International Conference on AIDS (1998).
Belanger D, et al. Identification of sub-groups at high risk of sharing needles among injection drug users participating in a needle-exchange program. World AIDS Conference 12th .
Abstract: Objective. To identify who are the drug users sharing injection material. Methods. In Quebec City, 618 injection drug users (IDU) who used the services of a needle syringe exchange program (8.4% HIV+) participated in a face-to-face interview. Information regarding behavioral variables related to the last 6 months as well as sociodemographic variables were obtained. A logistic regression analysis was performed on two models of sharing needles during the last 6 months. The first model compared those sharing IDU with those who do not; the second model was based only on sharing IDU and subdivided them in 3 groups: those who lended (n=78), borrowed (n=102), or lended and borrowed (n=153) injection material. Results. In the first model, several variables appeared to discriminate sharing IDU from non-sharing IDU. These variables were: living in a shooting gallery (OR: 4.6, CI95%: 1.5;14.2); the number of hits with the same needle syringe (OR greater than 1 hit: 2.9, CI95%: 1.8;4.6); injecting with an acquaintance (OR: 2.7, CI95%: 1.7;4.2); heroin users (OR: 2.2, CI 95%: 1.3;3.5); injecting in a shooting gallery (OR greater than 10 times: 2.1, CI95%: 1.2;3.6); for males, having male sexual partners (OR: 2.3, CI95%: 1.3;4.1) and age at the interview (OR: 0.97, CI95%: 0.95;0.99). In the second model, the discriminating variables differed between each logistic equation (IDU who lended/borrowed/lended and borrowed); and also differed from the variable in the first model. Conclusion. Important variables discriminate those who share from those who do not share. There is evidence that type of sharing is also related to specific variables.
This study was supported by a grant from the National Health Research and
Development Program, Health Canada.
Bruneau J, et al. (1997) High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. American Journal of Epidemiology 146:994-1002
Abstract: The association between NEP [needle exchange programs] use and HIV infection was examined in three risk assessment scenarios using intensive covariate adjustment for empirical confounders: a cross-sectional analysis of NEP use at entry as a determinant of seroprevalence, a cohort analysis of NEP use at entry as a predictor of subsequent seroconversion, and a nested case-control analysis of NEP participation during follow-up as a predictor of seroconversion. [...] Risk elevations for HIV infection associated with NEP attendance were substantial and consistent in all three risk assessment scenarios in our cohort of injection drug users, despite extensive adjustment for confounders. In summary, in Montreal, NEP users appear to have higher seroconversion rates than NEP nonusers. (Author) This research was funded by a grant from the National Health Research and
Development Program, Health Canada.
Bruneau J, Franco E, Lamothe F (1997) Assessing harm reduction strategies: the dilemma of observational studies. American Journal of Epidemiology 146:1007-1010
Bulwer P. Safe Injection Sites: Compelling the Government to Act. 2001. Vancouver, B.C., Pivot Legal Society.
Canadian HIV-AIDS Legal Network . Drug Use & Provision of Health & Social Services. 1999. Ottawa, Canadian HIV-AIDS Legal Network.
Canadian HIV-AIDS Legal Network . Injection Drug Use and HIV/AIDS: Essential Resources - Info Sheet #11. 1999. Ottawa, Canadian HIV-AIDS Legal Network.
Canadian HIV/AIDS Legal Network . Injection Drug Use and HIV/AIDS: The Facts . 1999. Ottawa, Canadian HIV-AIDS Legal Network.
Abstract: This is one of a series of 12 info sheets on injection drug use and HIV/AIDS: legal and ethical issues: 1. Injection Drug Use and HIV/AIDS: The Facts (# 9154); 2.The Current Legal Status of Drugs (#
9156); 3. Drug Use & Provision of Health and Social Services (# 9158); 4.Treatment (# 9160); 5. Prescription of Opiates & Controlled Stimulants (# 9162); 6. Drug Users & Studies of HIV/AIDS & Illegal Drugs (# 9164); 7. Information about the Use & Effects of Drugs (# 9166); 8. Needle Exchange Programs (# 9168); 9. Methadone Maintenance Treatment (# 9170); 10. Safe Injection Facilities (# 9172); 11. An Obligation to Act (# 9174); 12. Essential Resources (#9176); The information in this series of info sheets is taken from Injection Drug Use and HIV/AIDS: Legal and Ethical Issues (# 1115), prepared by the Canadian HIV/AIDS Legal Network, but was updated in 2002.
Caputo T, Weiler W, Anderson J . The Street Lifestyle Study. 1997. Ottawa, Office of Alcohol, Drugs and Dependency Issues, Health Canada.
Daum K . A Continuum of Abuse: Yesterday's Child Sex Abuse Victims are Today's Sexually Exploited Children and Tomorrow's Adult Sex Trade Workers. 1997. Vancouver, Downtown Eastside Youth Activities Society.
Downtown Eastside Community Crime Prevention/Revitalization Project . Managing the Corner of Main and Hastings for Health and Safety. 1999-2000. Vancouver.
Expert Committee on AIDS and Prisons . HIV/AIDS in prisons: final report of the Expert Committee on AIDS and
Prisons. 1994. Ottawa, Correctional Services of Canada.
Ford P . HIV/AIDS in prisons: HIV and Hep C seroprevalence and associated risk behaviours in a Canadian prison. Canadian HIV/AIDS Policy and Law Newsletter 4[2-3], 53-54. 1999.
Gold M, et al. Needle Exchange Programs: An Economic Evaluation of a Local Experience. Canadian Medical Association Journal 157, 255-262.
Graham D, O'Briain W, van Steenes J . Hearing the Stories, Charting the Changes: An Analysis of AIDS Vancouver's Project Sustain Case Management Database. 1998. Vancouver, AIDS Vancouver.
Graham KAH, Peters E . Aboriginal Communities and Urban Sustainability. 2002.
Gully PR, Tepper ML (1997) Hepatitis C. Canadian Medical Association Journal 156:1427-1430
Hankins C, et al. (1994) HIV infection among women in prison: an assessment of risk factors using a
nonnominal methodology. American Journal of Public Health 84:1637-1640
Abstract: The relative contributions of needle use practices and sexual behaviors to human immunodeficiency virus (HIV) antibody seropositivity among 394 women incarcerated in Quebec were determined by risk factor assessment and serology with a nonnominal methodology. HIV positivity was found in 6.9% (95% confidence interval [CI] = 4.6, 9.9) of all participants and in 13%
(95% CI = 8.6, 18.6) of women with a history of injection drug use. HIV seropositivity among women with a history of injection drug use was predicted by sexual or needle contact with a seropositive person, self-
reported genital herpes, and having had a regular sexual partner who injected drugs, but it was not predicted by prostitution. Nonnominal testing is an ethical alternative to mandatory and anonymous unlinked
testing among correctional populations.
Study supported by a grant from the National Health Research and Development Programme, Health Canada.
Hankins C . Needle Exchange: Panacea or Problem? Canadian Medical Association Journal 157, 275-277. 1997.
Health Canada . Canada Communicable Disease Report: supplement on Hepatitis C prevention and control: a public health consensus. National Consensus Conference. Ottawa.
Health Canada . Canada Communicable Disease Report: supplement on Prevention and control of Hepatitis C: guidelines and recommendations. National Meeting. Health Canada.
Health Canada . Hepatitis and injection drug use. 2001. Ottawa, Health Canada.
Health Canada . Hepatitis C and injection drug use: a focus on youth. 2001. Ottawa, Health Canada.
Health Canada . Hepatitis C open Forum "The next three years" . 2001. Ottawa, Health Canada.
Health Canada . HIV/AIDS among injection drug users in Canada. 1998. Ottawa, Health Canada.
Abstract: This report updates current information on the status of the HIV/AIDS epidemic among IDUs in Canada.
Health Canada . HIV/AIDS epidemiology among Aboriginal People in Canada. 1998. Ottawa, Health Canada.
Abstract: Some Aboriginal communities are at increased risk for HIV infection because of their low socioeconomic status and high rates of sexually transmitted diseases. This report updates current information on the status of the HIV/AIDS epidemic among Canada's Aboriginal people.
Health Canada . Injection drug use and HIV/AIDS: Health Canada's response to the report of
the Canadian HIV/AIDS Legal Network. 2001. Ottawa, Health Canada.
Notes: See also:
Injection drug use and HIV/AIDS: the Canadian HIV/AIDS Legal Network
reacts to Health Canada's response to the Network's 1999 report on
injection drug use and HIV/AIDS (# 9041)
Health Canada . Risk Behaviours Among Injection Drug Users in Canada. 2000. Health Canada .
Health Planning . Memo to Vancouver/Richmond Health Board - Harm Reduction. 1998.
Howard T, et al. To Serve and Protect: A Report on Policing in Vancouver's Downtown Eastside. 2002. Vancouver, Pivot Legal Society .
James S . Information Request Report CLR 1999-006 Housing and CHRP Participants. 1999. Vancouver, Department of Health Care and Epidemiology University of British Columbia.
Jones C . Fixing to Sue: Is There a Legal Duty to Establish Safe Injection Facilities in British Columbia? 2001. Vancouver, Pivot Legal Society.
Kali-Shiva AIDS Services . Taking Care of Business-A Peer Training & Resource Manual for HIV+ Injection Drug Users. 2000. Manitoba Aboriginal AIDS Task Force.
Project funded by AIDS Community Action Program, Health Canada.
La Régie régionale de la santé et des services sociaux de Montréal-Centre. Hépatite C ŕ Montréal : 27 000 personnes infectées dont 18 000 ignorent l'ętre. De vos patients sont-ils du nombre ?;Hepatitis C in Montréal: 27,000 people are infected, 18,000 of whom do not know. Are any of your patients among them? 2001.
Laurie ML, Green KL . Health risks and opportunities for harm reduction among injection-drug-
using clients of Saskatoon's needle exchange program. Canadian Journal of Public Health 91[ 5], 350-352. 2000.
Lawless S, Kippax S, Crawford J . Dirty, Diseased, and Undeserving: The Positioning of HIV Positive Women. Social Science and Medicine 43, 1371-1377. 1996.
Legare J, Bognar CJ . Hepatitis C - North Shore Health Region HIV/AIDS prevention, treatment and support: final report. 2000. Vancouver.
Leonard L, Navarro C, Pelude L, et al. The effectiveness of harm reduction strategies in modifying hepatitis C
infection among injection drug users in Canada. Canada Communicable Disease Report . Viral Hepatitis and Emerging Bloodborne Pathogens in Canada , 52-58. 2001.
Lior L, Stratton E . The Eastern Region Project: seroprevalence of HIV, Hepatitis B and Hepatitis C viruses and high risk behaviours among IDU and sexual partners of IDU. 1998. Halifax, Nova Scotia Department of Health.
MacPherson D . A Framework for Action - A Four-Pillar Approach to Drug Problems in Vancouver. 2000. Vancouver, City of Vancouver.
McAmmond D, Skirrow J . Care, treatment and support for injection drug users living with HIV/AIDS:
a consultation report. 1997. Ottawa, Health Canada.
McCulloch W, Howard E, Ivan A . Building Nutritional Health: HIV, Injection Drug Use, Poverty and Nutrition in Vancouver's Downtown Community. 1999. Vancouver, AIDS Vancouver.
McLean M . Vancouver Drug Epidemiology and Drug Crime Statistics 2000 -- Draft. 2000. Vancouver: Canadian Community Epidemiology Network on Drug Use (CCENDU).
McLeod A . Aboriginal Communities and HIV/AIDS: A Joint Project with the Canadian AIDS Society and the Canadian Aboriginal AIDS Network -- Final Report. 1997. Ottawa, Canadian AIDS Society.
Medical Services Branch HIV/AIDS Focus Group . Medical Services Branch Future Action: Decreasing the Incidence of HIV/AIDS. 1997. Medical Services Branch HIV/AIDS Focus Group.
Millar JS . HIV, Hepatitis, and Injection Drug Use in British Columbia -- Pay Now or Pay Later? 1998. Victoria, B.C., Ministry of Health and Ministry Responsible for Seniors.
Millson M (1990) AIDS-related knowledge, attitudes and behaviour in injection drug users attending a Toronto treatment facility. Canadian Journal of Public Health 81 :46-49
Myers T, et al. (1995) A comparison of the determinants of safe injecting and condom use among injecting drug users. Addiction 90:217-226
Notes: Correspondence to Ted Myers, PhD, HIV Social, Behavioural and Epidemiological Studies Unit, University of Toronto, 3rd Floor, McMurrich Building, 12 queen's Park Cres. W., Toronto, ON M5S 1A8.
Nguyen M, et al. HIV/AIDS among Aboriginal people in Canada: injection drug use, a main concern. World AIDS Conference 12th . 1998. Ottawa, Health Canada.
Abstract: OBJECTIVE: To examine the contribution of injection drug use (IDU) to HIV infection among Aboriginal people in Canada. METHODS: AIDS data were derived from the Canadian AIDS Case Reporting and Surveillance System. HIV testing data were obtained from the British Columbia (BC) Enhanced HIV Surveillance Study, the Northern Alberta (NA) HIV Clinic, the HIV testing
programs in Saskatchewan. HIV prevalence/risk behaviour data were obtained from 3 studies with Aboriginal identifiers: Vancouver IDU Cohort Study, Alberta STD clinic study, and Montreal street youth study. RESULTS: As of 30/09/97, 249/13 310 AIDS cases were reported among Aboriginal people in Canada. The proportion of adult Aboriginal AIDS cases (> age 15) attributed to IDU were 54.0% in women and 17.8% in men, with an additional 13.9% of adult men attributed to the category MSM/IDU. The proportion of cases attributed to IDU alone among adult Aboriginal AIDS cases has increased over time, from 3.2% (< 1989) to 10.4% (1989-92) and 35.3% (1993- 96). Recent HIV testing data (1993-97) in BC and Saskatchewan as well as HIV clinical data in NA all found that the IDU exposure category in
combination with other risk factors (MSM/Lesbian, sex trade, heterosexual contact) accounted for 52-60% of male HIV+ diagnoses and 40-75% of female HIV+ diagnoses. A history of IDU was also more common among Montreal street youth aged 13-25 years of Aboriginal background (43.7%, n = 71).
The Vancouver IDU cohort study found a significantly higher HIV prevalence among Aboriginal than non-Aboriginal persons (30.4% vs 21.1%, p = 0.01). In the Alberta STD clinic study, the 3 HIV+ cases in Aboriginal women (n = 226) were all associated with IDU while the 2 cases in non-Aboriginal
women (n = 2,677) were both attributed to heterosexual transmission. CONCLUSION: Evidence suggests that IDU is increasingly becoming an important risk factor for HIV infection among Aboriginal people in Canada, and appears to be involved in half or more of new infections. Therefore, targeted programs for Aboriginal IDU are urgently needed to slow the spread of HIV.
Palepu A, Tyndall MW, Leon H, et al. (2001) Hospital utilization and costs in a cohort of injection drug users. CMAJ 165:415-420
Parry P . "Something to eat, a place to sleep and someone who gives a damn": HIV/AIDS and Injection Drug Use in the DTES. 1997. Vancouver, Vancouver/Richmond Health Board.
Patrick DM, Buxton JA, Bigham M, et al. Public health and hepatitis C (# 9081). 91:19-23
Patrick DM, et al. The Incidence of Hepatitis C Virus Infection Among Injecting Drug Users During an Outbreak of HIV Infection--DRAFT 2000.
Patrick DM, Tyndall MW, Cornelisse PGA, et al. (2001) Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal 165:889-895
Patten S (In Press) The Transtheoretical Model of Behavior Change and Injection Drug Use. In: Mancoske R, Smith D (eds) Practice Models in HIV Services Southern University at New Orleans Press,
Patten S, Nielsen D (2003) Chapter 21: Injection Drug Users . In: HIV/AIDS Nursing Secrets: Questions and Answers Reveal the Secrets to Safe and Effective HIV/AIDS Nursing Hanley & Belfus, Philadelphia,
Patten S, Vollmann A, Thursten B (1999) HANDBOOK OF VIGNETTES DESCRIBING THE SOCIAL CONTEXT OF INJECTION DRUG USE IN CALGARY. In: Department of Community Health Sciences, Faculty of Medicine, University of Calgary
Poulin C, et al. HIV-1 infection and risk factors among injecting drug users (IDU) attending a needle exchange program in Quebec City. World AIDS Conference 12th . This work was supported by the National Health Research and Development Program, Health and Welfare Canada.
Abstract: Objective: To assess the impact of the needle exchange program (NEP) of Quebec City on HIV risk behaviours and to determine HIV prevalence and associated risk factors among IDU attenders. Methods: HIV prevalence and associated risk factors will be compared between IDU who began to attend
NEP recently (less than 2 months) and the others, at 3 time points (3 data collection cycles) over 2 years. For each collection, attenders who injected drugs during the previous 6 months will be asked to answer a questionnaire on risk behaviors and to provide an oral fluid sample. An encrypted code based on sex, date of birth, first and last initials will be used to follow participants over two years. Two data collection cycles have now been completed. Results: For the second collection, 339 IDUs (247 men and 91 women) accepted to participate. Nearly 65% have been attending the NEP since at least 2 months. The HIV prevalence was 11.8% (40/339); CI 95%: 8.6%-15.7%. The prevalence was significantly lower among IDU who
began to attend NEP recently than among the others: 4.2% vs 15.9%, p is less than 0.01. Through univariate analysis, HIV-positive IDUs were older and they reported more often previous imprisonment and a history of hepatitis. In addition, HIV infection was found to be associated with duration of intravenous drug use, having shared needles with HIV-positive IDU, having same sex partners and being involved in prostitution or having sexual partners with these risk factors. Nine of 108 negative subjects seroconverted for an incidence rate of 6.3 per 100 person-years.
Conclusions: Most of these results are similar to those obtained in the first collection and they are consistent with results previously reported about NEP attenders and non-attenders. The follow-up analyses will help to estimate the incidence rate among this population and to assess the impact of NEP on HIV behaviours.
Quastel N . Illegal Drug Addiction as a Disability. 2001. Vancouver, Pivet Legal Society.
Rabkin JGeal . Psychopathology in Male and Female HIV-Positive and Negative Injecting Drug Users: Longitudinal Course Over 3 Years. AIDS 11[507-515]. 1997.
Remis RS (2002) HIV Incidence Among Injection Drug Users in Vancouver. CMAJ 166:908-909
Rhodes T, et al (1998) Differences in sexual behaviour and condom use among cocaine and opioid injectors in Santos, Toronto and London. International Journal of Drug Policy 9:449-460 This research was supported by grants from the Medical Research Council and North Thames Regional Health Authority (London), National Health Research Development Programme of Health Canada and City of Toronto Department of Public Health (Toronto), and World Health Organization (Santos) with additional central coordination support provided by the World Health Organization.
Romanowski B, et al. Human immunodeficiency virus seroprevalence and risk behaviors in patients
attending sexually transmitted disease clinics in Alberta. International Society for STD Research Conference 11th . Research supported by the Divisions of STD Control and HIV/AIDS Epidemiology,
Laboratory Centre for Disease Control, Health Canada.
Abstract: OBJECTIVE: To investigate the dissemination of human immunodeficiency virus (HIV) and hepatitis C infection in association with sexually transmitted diseases (STDs), sexual practices, and injection drug use. All eligible men and women attending two STD clinics in Alberta, Canada, from May 1994 to May 1995 were studied. STUDY DESIGN: Anonymous, unlinked serosurveys were performed using leftover sera drawn for routine syphilis, hepatitis B, or HIV testing. Self-administered questionnaires collected a wide range of data: demographic, sexual behaviors, condom use, STD history, the exchange of drugs or money for sex, and drug and alcohol use. RESULTS: HIV seroprevalence in the overall sample group (n = 6,668) was 1.5%. Univariate analysis showed significant relationships for age between
30 years and 49 years, men having sex with men, injection drug use regardless of sexual orientation, history of STD, anal sex, and exchanging money or drugs for sex. At the multivariate level, only men having sex with men, injection drug use, and age more than 30 years remained predictive of HIV infection. The prevalence of hepatitis C was 3.4% with significant associations being injection drug use and exchanging money or drugs for sex. CONCLUSION: The behavioral associations between sex
practices, injection drug use, and HIV and hepatitis C seroprevalence warrant ongoing investigation. Continuing prevention programs targeted at safer sex practices (particularly for men having sex with men) and the use of clean needles are needed.
Rothon DA, et al (1997) Determinants of HIV-related high risk behaviours among young offenders: a window of opportunity. Canadian Journal of Public Health 88:14-17 Technical and financial support for this project was generously provided by the Bureau of Communicable Disease Epidemiology, LCDC, Health Canada,
Dr. Don Sutherland, Chief, Division of HIV/AIDS Epidemiology. Financial assistance was also received from the Medical Services Branch, Pacific Region, Health Canada.
Abstract: PURPOSE: To study HIV-associated risk behaviours among young offenders. METHODS: Juveniles aged 12 to 19 years entering correctional facilities in British Columbia volunteered in an unlinked anonymous study. Logistic regression was used to identify factors associated with high-risk sexual
behaviours and injection drug use (IDU). RESULTS: Despite low HIV prevalence (0.25%), patterns of risk behaviour were evident. IDU and homosexual/bisexual activity were equally prevalent among youth aged 12 to 15 and 16 to 19 years. For both age groups, IDU and female gender were significant predictors of sex for trade and sex with another drug user. Natives aged 12 to 15 years were five times more likely to inject drugs than non-Natives. However, predictors of IDU differed for older vs. younger youth. CONCLUSIONS: Patterns of high-risk activity begin early and selective pressures may differ for younger vs. older young offenders. Youth in detention provide a window of opportunity for enhanced HIV/AIDS
Rowell R (1997) Developing AIDS Services for Native Americans: Rural and Urban Contrasts. Journal-of-Gay-&-Lesbian-Social-Services 6:85-95
Abstract: Describes similarities & differences in the experiences of acquired immune deficiency syndrome (AIDS) programs targeting Navajos in rural Chinle, AZ, & Native Americans in New York City. Site-specific barriers that prevent or discourage access to health care for Native Americans living with human immunodeficiency virus/AIDS were identified. On the Navajo reservation, the critical issues were confidentiality, lack of faith in local medical services, & lack of access to nonlocal medical services (a function of both finances & transportation). In New York City, the critical issues were dual or multiple diagnosis (eg, substance addiction & tuberculosis infection), budget cuts, lack of adequate housing, & confusion about cultural values. 6 References. Adapted from the source document
Roy É . HIV infection among Montréal street youth: prevalence study. 1996. Montreal, Unité de santé publique.
Roy É, et al. Drug injection initiation among street youth. World AIDS Conference.
Supported by the Conseil québécois de la recherche sociale.
Abstract: BACKGROUND: In 1995, an epidemiological study showed that 36.1% of Montreal street youth had injected drugs. OBJECTIVES: To describe drug injection initiation among street youth and explore how initiation occurs within their drug use itinerary. METHODS: In an exploratory qualitative
study, in-depth semi-structured interviews were conducted with 25 new injection drug users (IDUs) (initiation < 4 years) aged 15-22 years. Participants were recruited among Montreal street youth through various means including outreach at street youth agencies and snowballing technique. RESULTS: Most participants started drug use around 12-13 years of age, experimented with a variety of drugs in the following years (pot, hash, acid, PCP, mushrooms) and started injecting within five years. Many seemed attracted by the experience of the injection itself (whatever the drug); a few were particularly attracted by heroin and believed injecting was the only way of taking that drug. Some were initiated into injection by friends or acquaintances, others asked to be injected or tried bythemselves. Girls tended to be more pro active, more self-reliant and more organized than boys regarding their first injection. Overall, initiation
of injection did not seem to be experienced by street youth as a major happening in their life. Indeed, their first injection was either idealized because of the 'trip' they had or seen as a casual event since 'everybody was doing it' and 'it's just another way of taking a drug'.
CONCLUSION: Initiation of injection among street youth does not seem to be the result of a dependence toward a specific drug. For these youth who are heavy users of multiple drugs, drug injection initiation appears to be just another way of experimenting with drug use.
Roy É, et al. (1998) Injection drug use among street youth: a dynamic process. Canadian Journal of Public Health 89:239-240
Réseau juridique canadien VIH/sida . L'injection de drogue et le VIH/sida: questions juridiques et éthiques:
documents de fond;Injection drug use and HIV/AIDS: legal and ethical issues. 1999. Montréal, QC, Réseau juridique canadien VIH/sida. Le financement de cette publication a été reçu de la Division des
politiques, de la coordination et des programmes sur le VIH/sida, Santé Canada, dans le cadre de la Stratégie canadienne sur le VIH/sida. Comprend les documents de fond suivants: Oscapella, Eugene; Elliot,
Richard. Analyse juridique de questions prioritaires (68 p.) --Roy, David. Commentaire éthique sur des questions piroritaires. (60 p.) --Riley, Diane. Questions de politiques. (66 p.).
Saskatchewan Health . At Risk. Saskatchewan Health.
Shields S . Enhanced surveillance of Canadian street youth, phase II: self identified Aboriginal youth: a sub analysis. Ottawa. 2000.
Single E . The economic implications of injection drug use. Conference on Injection Drug Use. 1999. Ottawa, Canadian Centre on Substance Abuse.
Abstract: Injection drug use involves a wide variety of adverse health and social consequences which have negative impacts on the economy. This presentation describes a recently developed set of guidelines for estimating the costs of substance abuse and presents findings from a cost estimation study utilizing these guidelines. It was estimated that 732 deaths, 31,147 years of potential life lost and 7,095 hospitalizations were attributable to illicit drug use in Canada in 1992 and that illicit drug use cost more
than $1.37 billion to the Canadian economy. The largest economic costs of illicit drug use are $823 million for lost productivity due to morbidity and premature mortality and $400 million for law enforcement and $88 million in direct health care costs. While it is not possible to distinguish the extent to which many of the costs are attributable to injection drug use rather than other aspects of illicit drug misuse, it is
clear that much of these costs result from injection drug use. The largest causes of drug-attributable death are suicide, overdose and AIDS contracted from sharing needles - all of which are strongly associated
with injection drug use.
Single E . Harm reduction as the basis for Hepatitis C policy and programming. Canadian Conference on Hepatitis C 1st . 32 . 2001. Ottawa, Canadian Centre on Substance Abuse.
Smart RG (1991) AIDS and drug abuse in Canada: current status and information needs. Journal of Drug Issues 21:73-82
Smart RG, et al. Drifting & doing: changes in drug use among Toronto street youth, 1990 and
1992. 1992. Toronto, ON, Addiction Research Foundation.
Spittal P, et al (2002) Risk Factors for Elevated HIV Incidence Rates Among Female Injection Drug Users in Vancouver. Canadian Medical Association Journal 166:894-899
Strathdee S . Canadian consortium for the Characterization of IDUs in Canada (CCIC):
phase I report-Vancouver, British Columbia. 1996. Vancouver, BC, University of British Columbia.
Strathdee S, et al (1997) Social determinants predict needle sharing behaviour among injection drug users in Vancouver. Addiction 92:1339-47
Strathdee Sea (1996) Current Trends in HIV/AIDS Epidemiology in British Columbia. BC MedicalJournal 36:98, 101, 103, 114-115
Strathdee S (1997) Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 11:59-65
Stratton E, et al. HIV, HBV and HCV and risk behaviours in a semi-rural community in Canada. World AIDS Conference . 1998.
Abstract: OBJECTIVE: 1. To estimate the seroprevalence of HIV, Hepatitis B (HBV) and Hepatitis C (HCV) among injection drug users (IDU) and persons who have ever had sex with an IDU (SIDU) in a semi-rural region of a small Canadian province and 2. To describe injection and sexual behaviours in this
population. METHODS: A voluntary, non-nominal, cross-sectional survey among IDU and SIDU was carried out with 3 components: an interviewer- administered risk behaviour questionnaire; a blood test (to test for HIV, HBV and HCV) (linked to the questionnaire by a unique study code); and pre-
and post-test counselling. Participants were recruited from the community as well as from the local correctional facility. Results are presented for participants aged 17 and up. RESULTS: 172 eligible adults were interviewed (92 IDU, 80 SIDU). Of the IDU, 77 were male; mean age: 30 years, mean age
at first injection: 22 years (range 12-47); 50% had been using injection drugs for at least one year; 33% had used injection drugs within the past 6 months; 80% had ever used cocaine. Seroprevalence of HIV was 5% (5/92), HBV core antibody 23% (21/91) and HCV antibody 47% (43/92). Among SIDU, 48 were males, mean age: 27 yrs. Over 1/2 did not know their sexual partners were IDUs at the time of their encounter. Persons were less likely to use condoms consistently with their casual IDU sex partners than with their casual non-IDU sex partners (68% never used condoms with their casual IDU partners, 50% never used condoms with their casual non-IDU partners). Seroprevalence of HIV antibody was 1% (1/80), HBV core antibody 5% (4/80) and HCV antibody 1% (1/80). CONCLUSION: In our study of a semi-rural population, we found behaviours and seroprevalence rates consistent with those found in urban and inner-city populations. The existence of HIV, HBV and HCV in our surveyed population demonstrates ongoing high risk behaviours among IDU and SIDU. Both risk groups reported risky behaviours which indicates the potential for continued transmission of these pathogens in this community.
Vancouver-Richmond Health Board . Harm Reduction. 1998. Vancouver, BC: Vancouver-Richmond Health Board.
Vancouver -Richmond Health Board . Reducing Harm: Considering the Role of Safe Injection Sites - (draft). 1999. Vancouver, Vancouver/Richmond Health Board.
Vancouver-Richmond Health Board: Working Committee . HIV/AIDS and injection drug use in the DTES.
Whynot E . Canadian Community Epidemiology Network on Drug Use. 1995. Vancouver, Vancouver Health Board.
Whynot E . Vancouver CCENDU. A Canadian Community Epidemiology Network on Drug Use Report. 1998.
Willms SM, Michael V. Hayes, Hulchanski JD . Housing for Persons with HIV Infection in Canada: Issues and Recommendations. CHS Research Bulletin [1-8]. 1991.
Zou S, Tepper M, Giulivi A . Canada Communicable Disease Report: Hepatitis C in Canada . Viral Hepatitis and Emerging Bloodborne Pathogens in Canada. 2001.